CRDF
Cardiff Oncology Inc
1.20$
-2.5%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2004 | 2005 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | -59.1% | -3.0% | +74.6% | -42.4% | +8.0% | +11.8% | +21.7% | +32.5% | -25.1% | -35.3% | +49.6% | -1.9% | +7.5% | +26.4% | +40.0% | -13.2% | |
| – | – | – | – | – | – | +81.3% | -99.6% | +4,093.3% | +175.0% | +4.7% | -67.0% | +1,769.7% | +0.7% | -95.5% | -60.0% | +99.0% | +1.5% | +123.8% | |
| – | – | – | -59.1% | -3.0% | -670.6% | – | – | -219.2% | – | – | – | – | +49.6% | -1.9% | +7.5% | +26.4% | +40.0% | -13.2% | |
| – | +203.1% | – | – | -75.3% | +110.8% | +105.6% | +68.8% | +58.9% | +41.7% | -47.5% | +3.6% | +36.7% | +0.7% | +54.7% | +56.0% | +21.2% | +12.2% | -4.1% | |
| – | +288.4% | -12.3% | -12.0% | +18.9% | +23.6% | +135.2% | -14.0% | +36.3% | +44.9% | +0.2% | -30.4% | -28.0% | +42.6% | +44.1% | +11.3% | -1.0% | -4.3% | +14.0% | |
| – | +246.8% | -30.8% | +85.1% | -42.7% | +63.8% | +106.6% | +38.9% | +64.1% | +52.3% | -41.8% | -26.9% | +4.7% | +14.9% | +50.2% | +37.9% | +13.9% | +7.5% | +0.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | +28.4% | -51.0% | -100.0% | – | +4,857.4% | +81.0% | -9.8% | -24.8% | -97.5% | +821.6% | -99.1% | +13,100.0% | +498.9% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -1,156.0% | – | -99.7% | +3,476.5% | +198.5% | -116.3% | – | -13.7% | -142.4% | – | – | – | – | -110.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.